Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Steven R. Loranger has been appointed to its board of directors. Loranger was most recently chief executive officer and president of leading global water technology company Xylem Inc., following his service as chairman, president and chief executive officer of ITT Corporation for seven years.
Prior to joining ITT, Loranger served as executive vice president and chief operating officer of Textron, Inc., and held executive positions at Honeywell International Inc. and its predecessor company, AlliedSignal, Inc.
“We are excited to welcome Steve to our board of directors, which will benefit from his decades of experience leading large, innovation-focused corporations,” said Michael A. Mussallem, Edwards’ chairman and CEO. “We look forward to his insights and global experience gained from service in a variety of highly regulated, high-tech industries with significant focus on quality.”
Currently, Loranger serves on the boards of directors of Xylem, Inc., the Smithsonian National Air and Space Museum and the Congressional Medal of Honor Foundation. He also served on the board of FedEx Corporation from 2006 to 2014.
A former U.S. Navy lieutenant, Loranger holds bachelor’s and master’s degrees from the University of Colorado.
Source: Edwards Lifesciences
The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.
The planned closures come as GSK has agreed to sell its cephalosporins antibiotics business to Sandoz, a division of Swiss pharma firm Novartis, for as much as US$500m.
“The launch of these new formulations provides the nutritional market with much-needed alternative coating systems that address clean label consumer preferences and are easy to implement,” says Kelly Boyer, vice president film coatings at Colorcon.
